|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||38.14 - 39.14|
|52 Week Range||33.80 - 69.43|
|Beta (3Y Monthly)||2.31|
|PE Ratio (TTM)||13.90|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.40|
Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is contracting Bearish sentimentShort interest | NeutralShort interest is moderately high for CBM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $3.46 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managersâ€™ Index (PMI) data, output in the Basic Materialsis falling. The rate of decline is significant relative to the trend shown over the past year. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000 liter reactor into one of its cGMP manufacturing facilities at the site. The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems, which have now been qualified and validated.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Cambrex Corporation's (NYSE:CBM) P/E ratio and reflect onRead More...
To receive further updates on this Cambrex Corporation (NYSE:CBM) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of Power Options Weekly today.This morning I'm recommending a bearish trade on Cambrex Corporation (NYSE:CBM), a life sciences company.While my indicators are giving bullish readings again this week, they dipped briefly into neutral territory this week as the S&P 500 struggled to clear its 200-day moving average. The rally from the late-December bottom remains intact, although we did get some economic news on Thursday that was somewhat concerning.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRetail sales dropped a seasonally adjusted 1.2% in December, which was the largest monthly drop since 2009. December is typically one of the stronger months for retail sales, as a lot of consumers do their holiday shopping that month, so this reading came as a surprise to Wall Street.Though I remain bullish in the near term, I am recommending a defensive position this morning in case the market makes a move to the downside. CBM missed earnings this week, and it has exposure in Europe, so I decided it would be a good downside play. Europe is StrugglingThe economic situation in Europe is not good at all. Their central bankers are all out of options for stimulating the region's economies, and that weakness has the potential to creep over into our markets eventually.Two of the three subsidiaries that own CBM's manufacturing facilities are located in Europe. CBM also has research and development facilities throughout Europe. If we do start to see Europe's economic issues affect our market, it will start with companies like CBM. No Support Above $30CBM reported earnings on Feb. 13, before market open, and it missed earnings estimates by over 90%. The stock dropped below support at the $36 level, and yesterday it dropped even further.Daily Chart of Cambrex Corporation (CBM) -- Chart Source: TradingViewCBM set a new 52-week low this week, and its next support level -- from early 2017 -- is at $30. The fundamental picture looks bad, and CBM doesn't have the technical support to keep the stock from falling further. That's why I'm recommending a bearish play this morning.Buy to open the Cambrex Corporation (CBM) April 18th $30 Puts (CBM190418P00030000) at $0.75 or lower. Note: The Good Friday holiday falls on April 19th, 2019. Because U.S. markets will be closed that day, April monthly options will expire the day before, on April 18th, 2019.Follow our Facebook page to receive each Trade of the Day direct to your News Feed -- and join the conversation.InvestorPlace advisor Ken Trester brings you Power Options Weekly, which delivers 5 new options trades and his latest trading advice to you each Friday. Trester has been trading options since the first exchanges opened in 1973 with a winning streak that goes back to 1984 with money-doubling average annual profits since 1990.Compare Brokers The post CBM Missed Earnings by Over 90% appeared first on InvestorPlace.
Cambrex (CBM) delivered earnings and revenue surprises of 2.86% and -15.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the East Rutherford, New Jersey-based company said it had profit of 4 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to $1.44 per share. The results ...
- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Conference call at 8:30 a.m. ET on February 13, 2019 -.
Cambrex (CBM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EAST RUTHERFORD, N.J., Feb. 08, 2019 -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
NEW YORK, Jan. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Cambrex Corporation (CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it has completed the acquisition of Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners. The transaction, announced on November 20, 2018, strengthens Cambrex’s position as the leading, fully integrated small molecule contract development and manufacturing organization (CDMO) across the entire drug lifecycle.
Is Cambrex Corporation (NYSE:CBM) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]